OMDA
BEARISH
$13.12
Live
Omada Health, Inc. · NASDAQ
Target $21.42
(+63.2%)
$10.28
52W Range
$28.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$773.1M
P/E
N/A
ROE
-8.7%
Profit margin
-4.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
OMDA exhibits a critical disconnect between high revenue growth and deteriorating financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company shows strong top-line expansion (58.1% YoY) and positive earnings surprises, the technical trend is completely bearish and insider sentiment is heavily negative. The high current ratio provides a liquidity cushion, but the aggressive selling by the CEO and other executives suggests a lack of internal confidence in the current valuation. Despite analyst 'Buy' recommendations and a higher target price, the fundamental health and price action indicate significant risk.
Key Strengths
Strong revenue growth of 58.10% YoY
High gross margins at 65.69%
Strong short-term liquidity with a current ratio of 3.60
Consistent earnings beats in 3 of the last 4 quarters
Positive operating margin of 4.33% indicating a path to profitability
Key Risks
Very weak Piotroski F-Score (2/9) indicating poor fundamental health
Heavy insider selling, specifically by the CEO and CFO
Severe price depreciation (-48.4% over the last 6 months)
Negative ROE (-8.68%) and Profit Margin (-4.91%)
High forward P/E (36.59) relative to current negative profitability
AI Fair Value Estimate
Based on comprehensive analysis
$15.5
+18.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
45
70
20
25
0
AI Verdict
High-risk growth play with deteriorating fundamentals
Key drivers: Revenue growth, Piotroski F-Score, Insider selling, Price momentum
Confidence
90%
Value
45/100
Ref P/E 36.59, P/S 2.97
Positives
- Price/Sales of 2.97 is reasonable for the sector
Watchpoints
- No Graham Number available due to inconsistent earnings
- Forward P/E is high
Future
70/100
Ref 58.10% Revenue Growth
Positives
- Exceptional YoY revenue growth
- Positive EPS surprises
Watchpoints
- Uncertainty in long-term profitability
Past
20/100
Ref Historical price trends
Positives
- Recent Q/Q EPS growth of 433.3%
Watchpoints
- 1Y price change of -43.0%
- 6M price change of -48.4%
Health
25/100
Ref Piotroski F-Score 2/9
Positives
- Current ratio of 3.60
Watchpoints
- Piotroski F-Score of 2/9
- Negative ROE and ROA
Dividend
0/100
Ref Dividend Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$13.12
Analyst Target
$21.42
Upside/Downside
+63.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OMDA and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OMDA
Omada Health, Inc.
Primary
|
-43.0% | -43.0% | -43.0% | -48.4% | -11.3% | +4.7% |
|
IART
Integra LifeSciences Holdings Corporation
Peer
|
-85.7% | -83.0% | -43.2% | -25.8% | +3.0% | +3.9% |
|
NUTX
Nutex Health Inc.
Peer
|
-98.2% | -8.0% | -21.6% | +2.8% | +17.6% | +3.8% |
|
KURA
Kura Oncology, Inc.
Peer
|
-69.7% | -27.5% | +54.0% | -12.0% | -6.0% | +0.7% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
OMD
Omada Health, Inc.
Primary
5Y
-43.0%
3Y
-43.0%
1Y
-43.0%
6M
-48.4%
1M
-11.3%
1W
+4.7%
IAR
Integra LifeSciences Holdings Corporation
Peer
5Y
-85.7%
3Y
-83.0%
1Y
-43.2%
6M
-25.8%
1M
+3.0%
1W
+3.9%
NUT
Nutex Health Inc.
Peer
5Y
-98.2%
3Y
-8.0%
1Y
-21.6%
6M
+2.8%
1M
+17.6%
1W
+3.8%
KUR
Kura Oncology, Inc.
Peer
5Y
-69.7%
3Y
-27.5%
1Y
+54.0%
6M
-12.0%
1M
-6.0%
1W
+0.7%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
36.59
PEG Ratio
N/A
P/B Ratio
3.34
P/S Ratio
2.97
EV/Revenue
2.12
EV/EBITDA
-84.98
Market Cap
$773.1M
Profitability
Profit margins and return metrics
Profit Margin
-4.91%
Operating Margin
4.33%
Gross Margin
65.69%
ROE
-8.68%
ROA
-3.28%
Growth
Revenue and earnings growth rates
Revenue Growth
+58.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
3.6
Strong
Quick Ratio
3.4
Excellent
Cash/Share
$3.77
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
70.8%
Op. Margin
4.3%
Net Margin
6.8%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.33x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
94%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-05
$0.16
+467.4% surprise
2025-11-06
$0.03
+143.7% surprise
2025-08-07
$-0.05
+59.1% surprise
Healthcare Sector Comparison
Comparing OMDA against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-8.68%
This Stock
vs
-100.15%
Sector Avg
-91.3%
(Below Avg)
Profit Margin
-4.91%
This Stock
vs
-13.63%
Sector Avg
-64.0%
(Weaker)
Revenue Growth
58.1%
This Stock
vs
121.05%
Sector Avg
-52.0%
(Slower)
Current Ratio
3.6
This Stock
vs
4.55
Sector Avg
-20.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OMDA
Omada Health, Inc.
|
BEARISH | $773.1M | - | -8.7% | -4.9% | $13.12 | |
|
IART
Integra LifeSciences...
|
NEUTRAL | $771.58M | - | -39.9% | -31.6% | $9.9 | Compare |
|
NUTX
Nutex Health Inc.
|
BEARISH | $770.84M | 10.3 | 58.9% | 8.1% | $109.0 | Compare |
|
KURA
Kura Oncology, Inc.
|
BEARISH | $765.82M | - | -94.8% | -% | $8.67 | Compare |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | Compare |
OMDA
Omada Health, Inc.
BEARISH
Mkt Cap
$773M
P/E
-
ROE
-8.7%
Price
$13.12
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-08 | SHAO WEI-LI | President | Sale | 2,829 | $35,946 |
| 2026-04-02 | KLAPSTEIN JULIE D | Director | Stock Award | 698 | - |
| 2026-04-02 | HILLEMAN JERYL L | Director | Stock Award | 1,544 | - |
| 2026-04-02 | FETTER TREVOR | Director | Stock Award | 955 | - |
| 2026-04-02 | ROOT JONATHAN D | Director | Stock Award | 882 | - |
| 2026-03-13 | COOK STEVEN L. | Chief Financial Officer | Sale | 1,884 | $26,263 |
| 2026-03-09 | DUFFY SEAN P M.D. | Chief Executive Officer | Sale | 4,063 | $58,276 |
| 2026-03-05 | SHAO WEI-LI | President | Stock Award | 264,705 | - |
| 2026-03-05 | GRACEY CRAIG | Officer | Stock Award | 16,470 | - |
| 2026-03-05 | COOK STEVEN L. | Chief Financial Officer | Stock Award | 147,058 | - |
| 2026-03-05 | DUFFY SEAN P M.D. | Chief Executive Officer | Stock Award | 323,529 | - |
| 2026-01-13 | DUFFY SEAN P M.D. | Chief Executive Officer | Sale | 271,275 | $4,245,926 |
| 2026-01-13 | DUFFY SEAN P M.D. | Chief Executive Officer | Option Exercise | 271,275 | $691,751 |
| 2026-01-05 | HILLEMAN JERYL L | Director | Stock Award | 1,601 | - |
| 2026-01-05 | FETTER TREVOR | Director | Stock Award | 991 | - |
SHAO WEI-LI
President
2026-04-08
2,829 shares
·
$35,946
KLAPSTEIN JULIE D
Director
2026-04-02
698 shares
HILLEMAN JERYL L
Director
2026-04-02
1,544 shares
FETTER TREVOR
Director
2026-04-02
955 shares
ROOT JONATHAN D
Director
2026-04-02
882 shares
COOK STEVEN L.
Chief Financial Officer
2026-03-13
1,884 shares
·
$26,263
DUFFY SEAN P M.D.
Chief Executive Officer
2026-03-09
4,063 shares
·
$58,276
SHAO WEI-LI
President
2026-03-05
264,705 shares
GRACEY CRAIG
Officer
2026-03-05
16,470 shares
COOK STEVEN L.
Chief Financial Officer
2026-03-05
147,058 shares
DUFFY SEAN P M.D.
Chief Executive Officer
2026-03-05
323,529 shares
DUFFY SEAN P M.D.
Chief Executive Officer
2026-01-13
271,275 shares
·
$4,245,926
DUFFY SEAN P M.D.
Chief Executive Officer
2026-01-13
271,275 shares
·
$691,751
HILLEMAN JERYL L
Director
2026-01-05
1,601 shares
FETTER TREVOR
Director
2026-01-05
991 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
12 analysts
Citizens
2026-04-14
Market Outperform
Goldman Sachs
2026-04-09
Buy
Buy
Evercore ISI Group
2026-04-08
Outperform
Outperform
JP Morgan
2026-03-12
Overweight
Overweight
Canaccord Genuity
2026-03-06
Buy
Buy
BMO Capital
2026-03-06
Outperform
Outperform
Morgan Stanley
2026-03-06
Overweight
Overweight
Barclays
2026-03-06
Overweight
Overweight
Barclays
2026-03-03
Overweight
Overweight
Needham
2026-01-22
Buy
Buy
Past News Coverage
Recent headlines mentioning OMDA from our newsroom.
Newest → oldest
No matching news yet.